Keith Flaherty
MD
Director of Clinical Research, Cancer Center
👥Biography 个人简介
Keith Flaherty led the pivotal trials that established BRAF inhibition (vemurafenib) and BRAF plus MEK inhibitor combinations (dabrafenib plus trametinib) as transformative treatments for BRAF V600E-mutant melanoma. His basic-to-clinical translational work defined the molecular basis of acquired resistance to BRAF inhibitors and prompted the development of rational combination strategies. He has also pioneered genomically driven clinical trial designs in oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Keith Flaherty 的研究动态
Follow Keith Flaherty's research updates
留下邮箱，当我们发布与 Keith Flaherty（Massachusetts General Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment